Symbols / BEAM $25.17 -0.59%
BEAM Chart
About
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.56B |
| Enterprise Value | 1.41B | Income | -79.99M | Sales | 139.74M |
| Book/sh | 12.48 | Cash/sh | 12.54 | Dividend Yield | — |
| Payout | 0.00% | Employees | 511 | IPO | — |
| P/E | — | Forward P/E | -5.82 | PEG | — |
| P/S | 18.35 | P/B | 2.02 | P/C | — |
| EV/EBITDA | -3.90 | EV/Sales | 10.08 | Quick Ratio | 12.85 |
| Current Ratio | 13.09 | Debt/Eq | 12.45 | LT Debt/Eq | — |
| EPS (ttm) | -0.81 | EPS next Y | -4.32 | EPS Growth | — |
| Revenue Growth | 279.50% | Earnings | 2026-05-05 | ROA | -18.55% |
| ROE | -8.11% | ROIC | — | Gross Margin | -193.12% |
| Oper. Margin | -15.29% | Profit Margin | -57.24% | Shs Outstand | 101.86M |
| Shs Float | 88.04M | Short Float | 24.13% | Short Ratio | 13.26 |
| Short Interest | — | 52W High | 36.44 | 52W Low | 13.53 |
| Beta | 2.17 | Avg Volume | 1.81M | Volume | 1.40M |
| Target Price | $49.93 | Recom | Strong_buy | Prev Close | $25.32 |
| Price | $25.17 | Change | -0.59% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$49.93
Mean price target
2. Current target
$25.17
Latest analyst target
3. DCF / Fair value
$-38.93
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$25.17
Low
$26.00
High
$80.00
Mean
$49.93
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-25 | main | RBC Capital | Sector Perform → Sector Perform | $26 |
| 2026-02-25 | main | Wedbush | Outperform → Outperform | $65 |
| 2026-02-20 | init | Canaccord Genuity | — → Buy | $74 |
| 2026-01-21 | main | Bernstein | Outperform → Outperform | $41 |
| 2026-01-07 | init | UBS | — → Neutral | $28 |
| 2025-11-24 | init | Evercore ISI Group | — → Outperform | $35 |
| 2025-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-10-09 | main | JP Morgan | Overweight → Overweight | $46 |
| 2025-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-08-06 | main | Barclays | Equal-Weight → Equal-Weight | $21 |
| 2025-05-07 | main | Guggenheim | Buy → Buy | $55 |
| 2025-05-07 | main | Wells Fargo | Overweight → Overweight | $70 |
| 2025-05-07 | main | Barclays | Equal-Weight → Equal-Weight | $25 |
| 2025-04-07 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-03-28 | up | B of A Securities | Neutral → Buy | $42 |
| 2025-03-12 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-10 | up | Scotiabank | Sector Perform → Sector Outperform | $40 |
| 2025-03-10 | up | Jones Trading | Hold → Buy | $34 |
| 2025-03-10 | reit | HC Wainwright & Co. | Buy → Buy | $80 |
| 2025-03-03 | main | Scotiabank | Sector Perform → Sector Perform | $25 |
- Beam Global weekly orders jump to $1.7M; stock climbs - MSN hu, 19 Mar 2026 11
- H.C. Wainwright reiterates Beam Therapeutics stock rating at buy - Investing.com ue, 03 Mar 2026 08
- (BEAM) Movement as an Input in Quant Signal Sets - Stock Traders Daily ue, 17 Mar 2026 14
- Best CRISPR Companies for 2026 and How to Invest in Them - The Motley Fool ue, 17 Mar 2026 21
- As energy costs swing, Beam Global lands $1.7M in smart city orders - Stock Titan ue, 17 Mar 2026 10
- Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS) - The Globe and Mail ue, 17 Mar 2026 13
- BEEM Reports $1.7M Weekly Sales Order: Should You Buy the Stock? - TradingView Wed, 18 Mar 2026 15
- Integral Health Asset Management LLC Decreases Stock Holdings in Beam Therapeutics Inc. $BEAM - MarketBeat Sat, 14 Mar 2026 08
- Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? - Yahoo Finance ue, 30 Dec 2025 08
- Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - Zacks Investment Research hu, 12 Mar 2026 15
- Where to Find Beam Stock Information: Crypto & Trading Platform Guide - Bitget ue, 17 Mar 2026 11
- What's Going On With Beam Therapeutics Stock? - Beam Therapeutics (NASDAQ:BEAM) - Benzinga ue, 24 Feb 2026 08
- Insider Sale: SVP of $BEAM Sells 6,198 Shares - Quiver Quantitative Mon, 26 Jan 2026 08
- Beam Therapeutics (NASDAQ:BEAM) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat Wed, 25 Feb 2026 08
- Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It? - TradingView hu, 12 Mar 2026 15
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 35000 | 595000 | — | Conversion of Exercise of derivative security at price 17.00 per share. | CIARAMELLA GIUSEPPE | President | — | 2026-02-24 00:00:00 | D |
| 1 | 35000 | 1120042 | — | Sale at price 32.00 per share. | CIARAMELLA GIUSEPPE | President | — | 2026-02-24 00:00:00 | D |
| 2 | 50000 | 33500 | — | Conversion of Exercise of derivative security at price 0.67 per share. | EVANS JOHN M. | Chief Executive Officer | — | 2026-01-30 00:00:00 | D |
| 3 | 50000 | 1443528 | — | Sale at price 28.27 - 29.74 per share. | EVANS JOHN M. | Chief Executive Officer | — | 2026-01-30 00:00:00 | D |
| 4 | 1371 | 46614 | — | Sale at price 34.00 per share. | BELLON CHRISTINE | Officer | — | 2026-01-22 00:00:00 | D |
| 5 | 6198 | 216933 | — | Sale at price 35.00 per share. | CAVANAGH BETHANY J | Officer and Treasurer | — | 2026-01-22 00:00:00 | D |
| 6 | 3034 | 91384 | — | Sale at price 30.12 per share. | CAVANAGH BETHANY J | Officer and Treasurer | — | 2026-01-20 00:00:00 | D |
| 7 | 18629 | 644832 | — | Sale at price 33.62 - 35.40 per share. | BELLON CHRISTINE | Officer | — | 2026-01-15 00:00:00 | D |
| 8 | 6294 | 170567 | — | Sale at price 27.10 per share. | EMANY SRAVAN KUMAR | Chief Financial Officer | — | 2025-12-31 00:00:00 | D |
| 9 | 1254 | 33983 | — | Sale at price 27.10 per share. | BELLON CHRISTINE | Officer | — | 2025-12-31 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | -283.92K | 13.23M |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.21 |
| NormalizedEBITDA | -366.22M | -373.75M | -145.60M | -378.91M |
| TotalUnusualItems | 4.82M | -10.23M | -1.35M | 63.00M |
| TotalUnusualItemsExcludingGoodwill | 4.82M | -10.23M | -1.35M | 63.00M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -79.99M | -376.74M | -132.53M | -289.09M |
| ReconciledDepreciation | 22.29M | 31.59M | 29.53M | 22.58M |
| EBITDA | -361.40M | -383.98M | -146.95M | -315.90M |
| EBIT | -383.69M | -415.57M | -176.49M | -338.48M |
| NetInterestIncome | 43.73M | 49.09M | 46.68M | 15.30M |
| NormalizedIncome | -84.81M | -366.51M | -131.46M | -338.86M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -79.99M | -376.74M | -132.53M | -289.09M |
| TotalExpenses | 523.44M | 479.09M | 554.19M | 399.40M |
| TotalOperatingIncomeAsReported | -383.69M | -415.57M | -176.49M | -338.48M |
| DilutedAverageShares | 98.91M | 82.31M | 77.15M | 70.02M |
| BasicAverageShares | 98.91M | 82.31M | 77.15M | 70.02M |
| DilutedEPS | -0.81 | -4.58 | -1.72 | -4.13 |
| BasicEPS | -0.81 | -4.58 | -1.72 | -4.13 |
| DilutedNIAvailtoComStockholders | -79.99M | -376.74M | -132.53M | -289.09M |
| NetIncomeCommonStockholders | -79.99M | -376.74M | -132.53M | -289.09M |
| NetIncome | -79.99M | -376.74M | -132.53M | -289.09M |
| NetIncomeIncludingNoncontrollingInterests | -79.99M | -376.74M | -132.53M | -289.09M |
| NetIncomeContinuousOperations | -79.99M | -376.74M | -132.53M | -289.09M |
| EarningsFromEquityInterestNetOfTax | 0.00 | 0.00 | -25.50M | 0.00 |
| TaxProvision | 0.00 | 39.00K | 1.37M | 3.41M |
| PretaxIncome | -79.99M | -376.70M | -131.16M | -260.18M |
| OtherIncomeExpense | 259.97M | -10.23M | -1.35M | 63.00M |
| SpecialIncomeCharges | 180.00K | 1.59M | 9.74M | 18.90M |
| RestructuringAndMergernAcquisition | -180.00K | -1.59M | -9.74M | -18.90M |
| EarningsFromEquityInterest | 255.15M | 0.00 | 0.00 | 17.69M |
| GainOnSaleOfSecurity | 4.64M | -11.82M | -11.09M | 44.10M |
| NetNonOperatingInterestIncomeExpense | 43.73M | 49.09M | 46.68M | 15.30M |
| TotalOtherFinanceCost | -43.73M | -49.09M | -46.68M | -15.30M |
| OperatingIncome | -383.69M | -415.57M | -176.49M | -338.48M |
| OperatingExpense | 523.44M | 479.09M | 554.19M | 399.40M |
| ResearchAndDevelopment | 409.62M | 367.56M | 437.38M | 311.59M |
| SellingGeneralAndAdministration | 113.82M | 111.53M | 116.81M | 87.81M |
| GeneralAndAdministrativeExpense | 113.82M | 111.53M | 116.81M | 87.81M |
| OtherGandA | 113.82M | 111.53M | 116.81M | 87.81M |
| TotalRevenue | 139.74M | 63.52M | 377.71M | 60.92M |
| OperatingRevenue | 139.74M | 63.52M | 377.71M | 60.92M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 101.75M | 83.63M | 81.63M | 71.28M |
| ShareIssued | 101.75M | 83.63M | 81.63M | 71.28M |
| TotalDebt | 154.12M | 161.43M | 172.69M | 179.00M |
| TangibleBookValue | 1.24B | 733.54M | 981.33M | 733.47M |
| InvestedCapital | 1.24B | 733.54M | 981.33M | 733.47M |
| WorkingCapital | 1.17B | 696.08M | 1.01B | 869.30M |
| NetTangibleAssets | 1.24B | 733.54M | 981.33M | 733.47M |
| CapitalLeaseObligations | 154.12M | 161.43M | 172.69M | 179.00M |
| CommonStockEquity | 1.24B | 733.54M | 981.33M | 733.47M |
| TotalCapitalization | 1.24B | 733.54M | 981.33M | 733.47M |
| TotalEquityGrossMinorityInterest | 1.24B | 733.54M | 981.33M | 733.47M |
| StockholdersEquity | 1.24B | 733.54M | 981.33M | 733.47M |
| GainsLossesNotAffectingRetainedEarnings | 1.11M | 679.00K | 604.00K | -2.43M |
| OtherEquityAdjustments | 1.11M | 679.00K | 604.00K | -2.43M |
| RetainedEarnings | -1.64B | -1.57B | -1.19B | -1.06B |
| AdditionalPaidInCapital | 2.88B | 2.30B | 2.17B | 1.79B |
| CapitalStock | 1.02M | 836.00K | 816.00K | 712.00K |
| CommonStock | 1.02M | 836.00K | 816.00K | 712.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 242.82M | 370.28M | 478.38M | 608.24M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 145.88M | 188.21M | 272.82M | 384.64M |
| OtherNonCurrentLiabilities | 6.12M | 1.64M | 3.02M | 13.84M |
| DerivativeProductLiabilities | 0.00 | 5.40M | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | 33.22M | 109.89M | 202.18M |
| NonCurrentDeferredRevenue | 0.00 | 33.22M | 109.89M | 202.18M |
| LongTermDebtAndCapitalLeaseObligation | 139.76M | 147.96M | 159.91M | 168.62M |
| LongTermCapitalLeaseObligation | 139.76M | 147.96M | 159.91M | 168.62M |
| LongTermDebt | 3.01M | |||
| CurrentLiabilities | 96.94M | 182.07M | 205.56M | 223.59M |
| OtherCurrentLiabilities | 12.40M | 16.21M | 39.44M | 30.56M |
| CurrentDeferredLiabilities | 6.66M | 108.86M | 68.71M | 135.97M |
| CurrentDeferredRevenue | 6.66M | 108.86M | 68.71M | 135.97M |
| CurrentDebtAndCapitalLeaseObligation | 14.36M | 13.47M | 12.78M | 10.38M |
| CurrentCapitalLeaseObligation | 14.36M | 13.47M | 12.78M | 10.38M |
| CurrentDebt | 2.29M | |||
| OtherCurrentBorrowings | 2.29M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 29.34M | 21.57M | 21.77M | 19.12M |
| PayablesAndAccruedExpenses | 34.17M | 21.96M | 62.87M | 27.56M |
| CurrentAccruedExpenses | 23.94M | 18.09M | 61.25M | 18.53M |
| Payables | 10.23M | 3.87M | 1.62M | 9.03M |
| AccountsPayable | 10.23M | 3.87M | 1.62M | 9.03M |
| TotalAssets | 1.48B | 1.10B | 1.46B | 1.34B |
| TotalNonCurrentAssets | 212.49M | 225.68M | 248.67M | 248.82M |
| OtherNonCurrentAssets | 7.31M | 9.40M | 10.87M | 14.69M |
| NetPPE | 205.18M | 216.28M | 237.81M | 234.13M |
| AccumulatedDepreciation | -94.13M | -72.11M | -50.18M | -30.17M |
| GrossPPE | 299.31M | 288.38M | 287.99M | 264.30M |
| Leases | 110.76M | 101.19M | 100.19M | 85.80M |
| ConstructionInProgress | 2.82M | 2.53M | 5.28M | 5.20M |
| OtherProperties | 177.72M | 176.65M | 174.52M | 165.90M |
| MachineryFurnitureEquipment | 8.01M | 8.01M | 8.00M | 7.41M |
| BuildingsAndImprovements | 102.72M | |||
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.27B | 878.15M | 1.21B | 1.09B |
| OtherCurrentAssets | 23.48M | 27.41M | 21.17M | 14.76M |
| PrepaidAssets | 7.36M | |||
| Receivables | 0.00 | 300.00M | ||
| AccountsReceivable | 0.00 | 300.00M | ||
| CashCashEquivalentsAndShortTermInvestments | 1.25B | 850.74M | 1.19B | 1.08B |
| OtherShortTermInvestments | 950.27M | 568.77M | 753.98M | 845.37M |
| CashAndCashEquivalents | 294.94M | 281.97M | 435.89M | 232.77M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -360.05M | -356.19M | -182.93M | -26.42M |
| RepaymentOfDebt | 0.00 | -485.00K | -2.25M | -2.29M |
| IssuanceOfDebt | 0.00 | 0.00 | ||
| IssuanceOfCapitalStock | 470.51M | 0.00 | 270.17M | 108.26M |
| CapitalExpenditure | -14.95M | -8.95M | -33.73M | -48.95M |
| InterestPaidSupplementalData | 0.00 | 32.00K | 160.00K | 376.00K |
| EndCashPosition | 301.62M | 290.11M | 444.61M | 245.52M |
| BeginningCashPosition | 290.11M | 444.61M | 245.52M | 572.74M |
| ChangesInCash | 11.51M | -154.50M | 199.09M | -327.22M |
| FinancingCashFlow | 478.05M | 7.74M | 276.45M | 111.59M |
| CashFlowFromContinuingFinancingActivities | 478.05M | 7.74M | 276.45M | 111.59M |
| NetOtherFinancingCharges | -631.00K | -188.00K | -8.82M | |
| ProceedsFromStockOptionExercised | 7.54M | 8.22M | 9.16M | 5.81M |
| NetPreferredStockIssuance | 0.00 | |||
| PreferredStockIssuance | 0.00 | |||
| NetCommonStockIssuance | 470.51M | 0.00 | 270.17M | 108.26M |
| CommonStockIssuance | 470.51M | 0.00 | 270.17M | 108.26M |
| NetIssuancePaymentsOfDebt | 0.00 | -485.00K | -2.25M | -2.29M |
| NetLongTermDebtIssuance | 0.00 | -485.00K | -2.25M | -2.29M |
| LongTermDebtPayments | 0.00 | -485.00K | -2.25M | -2.29M |
| LongTermDebtIssuance | 0.00 | 0.00 | ||
| InvestingCashFlow | -121.44M | 185.01M | 71.84M | -461.34M |
| CashFlowFromContinuingInvestingActivities | -121.44M | 185.01M | 71.84M | -461.34M |
| NetInvestmentPurchaseAndSale | -361.56M | 193.95M | 105.57M | -412.38M |
| SaleOfInvestment | 848.23M | 680.39M | 1.09B | 1.20B |
| PurchaseOfInvestment | -1.21B | -486.44M | -984.34M | -1.62B |
| NetBusinessPurchaseAndSale | 255.07M | 0.00 | 0.00 | 0.00 |
| SaleOfBusiness | 255.15M | 0.00 | 0.00 | 0.00 |
| PurchaseOfBusiness | -78.00K | 0.00 | 0.00 | |
| NetPPEPurchaseAndSale | -14.95M | -8.95M | -33.73M | -48.95M |
| PurchaseOfPPE | -14.95M | -8.95M | -33.73M | -48.95M |
| OperatingCashFlow | -345.10M | -347.25M | -149.19M | 22.53M |
| CashFlowFromContinuingOperatingActivities | -345.10M | -347.25M | -149.19M | 22.53M |
| ChangeInWorkingCapital | -131.02M | -110.22M | -116.45M | 251.63M |
| ChangeInOtherWorkingCapital | -135.42M | -36.52M | -159.56M | -35.92M |
| ChangeInOtherCurrentLiabilities | -13.84M | -12.48M | -10.36M | 9.86M |
| ChangeInOtherCurrentAssets | 0.00 | 0.00 | -197.00K | |
| ChangeInPayablesAndAccruedExpense | 13.72M | -55.88M | 60.09M | -14.56M |
| ChangeInAccruedExpense | 7.68M | -57.69M | 67.66M | -16.93M |
| ChangeInPayable | 6.04M | 1.81M | -7.58M | 2.37M |
| ChangeInAccountPayable | 6.04M | 1.81M | -7.58M | 2.37M |
| ChangeInPrepaidAssets | 4.51M | -5.35M | -6.47M | -7.75M |
| ChangeInReceivables | 0.00 | -146.00K | 300.00M | -300.00M |
| OtherNonCashItems | 24.71M | -1.59M | -9.74M | -18.90M |
| StockBasedCompensation | 94.24M | 120.66M | 98.65M | 84.32M |
| UnrealizedGainLossOnInvestmentSecurities | -3.94M | 14.09M | 18.59M | -20.20M |
| AmortizationOfSecurities | -15.96M | -22.77M | -29.74M | -9.41M |
| DepreciationAmortizationDepletion | 22.29M | 31.59M | 29.53M | 22.58M |
| DepreciationAndAmortization | 22.29M | 31.59M | 29.53M | 22.58M |
| Depreciation | 22.29M | 31.59M | 29.53M | 22.58M |
| OperatingGainsLosses | -255.45M | -2.27M | -7.50M | 1.60M |
| EarningsLossesFromEquityInvestments | 0.00 | 0.00 | 25.50M | 0.00 |
| GainLossOnInvestmentSecurities | -301.00K | -2.27M | -7.50M | -23.90M |
| GainLossOnSaleOfBusiness | -255.15M | 0.00 | 0.00 | |
| NetIncomeFromContinuingOperations | -79.99M | -376.74M | -132.53M | -289.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BEAM
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|